96. クローン病 Crohn disease Clinical trials / Disease details
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
Showing 1 to 10 of 177 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05705856 (ClinicalTrials.gov) | February 15, 2023 | 15/1/2023 | Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease | Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease: a Retrospective Observational Study Effectiveness and Safety of UstekinumabIntensification in Crohn's Disease: a Retrospective Observati ... | Crohn Disease | Drug: Ustekinumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Not yet recruiting | 18 Years | N/A | All | 200 | NULL | |
2 | JPRN-jRCT2031220186 | 10/08/2022 | 06/07/2022 | A Basket Long-term Extension Study of Ustekinumab in Pediatric Participants | A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age) A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumabin Pediatric Cli ... | Crohn Disease, Ulcerative Colitis, Psoriatic Arthritis | Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004 & CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Ustekinumab will be administered as a SC injection. Participants will have continued access to ustekinumabfor primary study (CNTO1275CRD1001, CNTO1275PU ... | Nishikawa Kazuko | NULL | Pending | >= 2age old | < 18age old | Both | 151 | Phase 3 | France;Poland;United States Of America;Japan |
3 | NCT03712826 (ClinicalTrials.gov) | July 24, 2022 | 16/8/2018 | Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Bi ... | Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Bi ... | Crohn Disease | Drug: Anti-TNF Drug;Drug: Ustekinumab | Hospices Civils de Lyon | NULL | Withdrawn | 18 Years | N/A | All | 0 | N/A | France |
4 | NCT05387031 (ClinicalTrials.gov) | May 26, 2022 | 17/5/2022 | Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing Crohn's Disease Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing C ... | Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing Crohn's Disease: a Multicentre, Prospective, Observational Cohort Study Efficacy of Ustekinumab-based Integrated Medicine Therapy in Patients With Symptomatic Stricturing C ... | Crohn Disease;Stricture; Bowel;Intestinal Stricture | Drug: Ustekinumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Sixth Affiliated Hospital, Sun Yat-sen University;Second Affiliated Hospital of Soochow University;Chongqing Renji Hospital, University of Chinese Academy of Sciences Sixth Affiliated Hospital, Sun Yat-sen University;Second Affiliated Hospital of Soochow University;C ... | Recruiting | 18 Years | 65 Years | All | 400 | China | |
5 | EUCTR2020-004457-76-HU (EUCTR) | 17/05/2022 | 10/03/2022 | A Long-term Extension Study of Ustekinumab in Pediatric Participants with different medical conditions. A Long-term Extension Study of Ustekinumabin Pediatric Participants with different medical condition ... | A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age) - UNITED A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumabin Pediatric Cli ... | Paediatric conditions in - Moderately to Severely Active Crohn's Disease - Moderately to Severely Active Ulcerative Colitis - Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] Paediatric conditions in - Moderately to Severely Active Crohn's Disease - Moderately to Severely Ac ... | Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 INN or Proposed INN: Ustekinumab Other descriptive name: USTEKINUMAB Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 INN or Proposed INN: Ustekinumab Other descriptive name: USTEKINUMAB Trade Name: STELARA® Product Name: Ustekinumab Product Code: CNTO1275 INN or Proposed INN: Ustekinumab O ... | Janssen-Cilag International NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 151 | Phase 3 | United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;France;Hungary;Argentina;Belgium;Poland;Germany;Japan United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;France;Hungary;Argentina;Belgium; ... | ||
6 | NCT05242458 (ClinicalTrials.gov) | March 21, 2022 | 15/2/2022 | A Study of Ustekinumab Treatment in Children With Crohn's Disease | Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children With Crohn's Disease: A Retrospective Cohort Study Using the ImproveCareNow Registry Data Real-world Evidence for the Effectiveness and Safety of UstekinumabTreatment in Children With Crohn' ... | Crohn's Disease | Drug: Ustekinumab | Janssen Research & Development, LLC | ImproveCareNow (ICN);Children's Hospital Medical Center, Cincinnati | Recruiting | 2 Years | 25 Years | All | 662 | United States | |
7 | ChiCTR2200055424 | 2022-01-11 | 2022-01-09 | Transabdominal ultrasound evaluation of transmural healing of ustekinumab in Chinese patients with active Crohn's disease: a multicenter prospective study Transabdominal ultrasound evaluation of transmural healing of ustekinumabin Chinese patients with ac ... | Transabdominal ultrasound evaluation of transmural healing of ustekinumab in Chinese patients with active Crohn's disease: a multicenter prospective study Transabdominal ultrasound evaluation of transmural healing of ustekinumabin Chinese patients with ac ... | Crohn's disease (CD) | Experimental group:Ustekinumab therapy; | Drum Tower Hospital Affiliated to Nanjing University School of Medicine | NULL | Recruiting | 18 | 80 | Both | Experimental group:38; | Phase 4 | China |
8 | NCT04779762 (ClinicalTrials.gov) | January 2022 | 28/2/2021 | Stelara and Diet Trial for Crohns Disease | Stelara and CDED Diet Trial for Crohns Disease | Crohn Disease | Other: Crohn's disease exclusion diet (CDED);Drug: Ustekinumab Injection [Stelara] | Wolfson Medical Center | Sheba Medical Center, Israel | Not yet recruiting | 18 Years | 65 Years | All | 40 | N/A | Israel |
9 | EUCTR2020-004527-16-IT (EUCTR) | 21/12/2021 | 29/09/2021 | A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s Disease | A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment - InCharge A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, ph ... | Crohn`s Disease (CD) MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn`s Disease (CD) MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disea ... | Trade Name: Stelara 130mg / 26mL concentrate for solution for infusion Product Name: Stelara 130mg / 26mL concentrate for solution for infusion Product Code: [Stelara 130mg / 26mL concentrate for solution for INN or Proposed INN: USTEKINUMAB Product Name: BI 706321 Product Code: [BI 706321] Product Name: BI 706321 Product Code: [BI 706321] Product Name: BI 706321 Product Code: [BI 706321] Trade Name: STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML Product Name: Stelara 90mg/1ml solution for injection in pre-filled syringe (PFS) Product Code: [Stelara 90mg/1ml solution for injecti Trade Name: Stelara130mg / 26mL concentrate for solution forinfusion Product Name: Stelara130mg / 26m ... | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | France;United States;Czechia;Spain;Poland;Belgium;Italy | ||
10 | NCT05029921 (ClinicalTrials.gov) | December 10, 2021 | 30/8/2021 | A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease A Study of Ustekinumab(STELARA) in Chinese Participants With Moderately to Severely Active Crohn's D ... | A Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (STELARA), an Anti-Interleukin-12/23 Monoclonal Antibody, in Chinese Participants With Moderately to Severely Active Crohn's Disease A Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of ... | Crohn Disease | Drug: Ustekinumab | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | N/A | All | 180 | Phase 4 | China |